Ensho Health today announced three abstracts validating the Apollo automated electronic data capture ("aEDC") system for Cardiology real world evidence have been accepted for poster discussion and presentations at ISPOR 2022 to be held May 16-18.
"These studies demonstrate the unique capabilities of the Apollo aEDC system in secondary use of data studies,” said Dr. Taha Bandukwala, Ensho Health Co-Founder and Chief Medical Officer. "We believe the ability of Apollo to extract nuanced clinical insights from unstructured documents through natural language processing and other techniques can transform real world clinical research."
The research summarized in the abstracts was supported by Novartis Canada.
About Ensho Health
Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.